Back to Search Start Over

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.

Authors :
Horne EMF
Hulme WJ
Keogh RH
Palmer TM
Williamson EJ
Parker EPK
Green A
Walker V
Walker AJ
Curtis H
Fisher L
MacKenna B
Croker R
Hopcroft L
Park RY
Massey J
Morley J
Mehrkar A
Bacon S
Evans D
Inglesby P
Morton CE
Hickman G
Davy S
Ward T
Dillingham I
Goldacre B
Hernán MA
Sterne JAC
Source :
BMJ (Clinical research ed.) [BMJ] 2022 Jul 20; Vol. 378, pp. e071249. Date of Electronic Publication: 2022 Jul 20.
Publication Year :
2022

Abstract

Objective: To estimate waning of covid-19 vaccine effectiveness over six months after second dose.<br />Design: Cohort study, approved by NHS England.<br />Setting: Linked primary care, hospital, and covid-19 records within the OpenSAFELY-TPP database.<br />Participants: Adults without previous SARS-CoV-2 infection were eligible, excluding care home residents and healthcare professionals.<br />Exposures: People who had received two doses of BNT162b2 or ChAdOx1 (administered during the national vaccine rollout) were compared with unvaccinated people during six consecutive comparison periods, each of four weeks.<br />Main Outcome Measures: Adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, positive SARS-CoV-2 test, and non-covid-19 related death comparing vaccinated with unvaccinated people. Waning vaccine effectiveness was quantified as ratios of adjusted hazard ratios per four week period, separately for subgroups aged ≥65 years, 18-64 years and clinically vulnerable, 40-64 years, and 18-39 years.<br />Results: 1 951 866 and 3 219 349 eligible adults received two doses of BNT162b2 and ChAdOx1, respectively, and 2 422 980 remained unvaccinated. Waning of vaccine effectiveness was estimated to be similar across outcomes and vaccine brands. In the ≥65 years subgroup, ratios of adjusted hazard ratios for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test ranged from 1.19 (95% confidence interval 1.14 to 1.24)to 1.34 (1.09 to 1.64) per four weeks. Despite waning vaccine effectiveness, rates of covid-19 related hospital admission and death were substantially lower among vaccinated than unvaccinated adults up to 26 weeks after the second dose, with estimated vaccine effectiveness ≥80% for BNT162b2, and ≥75% for ChAdOx1. By weeks 23-26, rates of positive SARS-CoV-2 test in vaccinated people were similar to or higher than in unvaccinated people (adjusted hazard ratios up to 1.72 (1.11 to 2.68) for BNT162b2 and 1.86 (1.79 to 1.93) for ChAdOx1).<br />Conclusions: The rate at which estimated vaccine effectiveness waned was consistent for covid-19 related hospital admission, covid-19 related death, and positive SARS-CoV-2 test and was similar across subgroups defined by age and clinical vulnerability. If sustained to outcomes of infection with the omicron variant and to booster vaccination, these findings will facilitate scheduling of booster vaccination.<br />Competing Interests: Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: funding for this work from the Longitudinal Health and Wellbeing COVID-19 National Core Study, Asthma UK, and the NIHR; BG has received research funding from the Laura and John Arnold Foundation, the NIHR, the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organization, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he receives personal income from speaking and writing for lay audiences on the misuse of science; he is also a non-executive director of NHS Digital; AM is on the NHS Digital Professional Advisory Group (representing the Royal College of General Practitioners), advising on the use of general practice data for covid-19 related research and planning; until September 2019 he was interim chief medical officer of NHS Digital.<br /> (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
1756-1833
Volume :
378
Database :
MEDLINE
Journal :
BMJ (Clinical research ed.)
Publication Type :
Academic Journal
Accession number :
35858698
Full Text :
https://doi.org/10.1136/bmj-2022-071249